Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 23.4% is a hypertonic saline solution that increases serum osmolality, drawing water from intracellular space into extracellular space, thereby expanding intravascular volume and reducing cerebral edema. It also acts as an electrolyte replenisher.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of symptomatic hyponatremia,Reduction of intracranial pressure in patients with cerebral edema or increased intracranial pressure,Management of severe hypovolemia when rapid volume expansion is needed
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
IV: 50-100 m L of 23.4% sodium chloride (11.7-23.4 g Na Cl) infused over 1-2 hours for hyponatremia; rate not to exceed 0.5 m Eq/L/h correction.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable as a terminal elimination half-life; sodium and chloride are electrolytes regulated by homeostatic mechanisms; plasma concentrations normalize within minutes to hours depending on volume status and renal function.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Sodium and chloride are not metabolized; they are excreted primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal; >95% of administered sodium and chloride ions excreted unchanged in urine via glomerular filtration and tubular reabsorption/regulation; negligible biliary/fecal elimination.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Minimal to none; sodium and chloride are not significantly bound to plasma proteins (<0.1% bound).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Approximately 0.15-0.3 L/kg; corresponds to extracellular fluid volume; sodium distributes primarily in extracellular space with minimal intracellular penetration.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%; no oral or other relevant routes for the 23.4% hypertonic solution; oral bioavailability not applicable due to enteral use of different formulations.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR >60: no adjustment; GFR 30-59: caution, monitor sodium; GFR 15-29: avoid if possible; GFR <15: contraindicated.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A/B: standard dosing with caution; Child-Pugh C: avoid due to risk of fluid overload and encephalopathy.
No dosage adjustment required for hepatic impairment.
For hyponatremia: 0.5-1 m L/kg 23.4% Na Cl (2-4 m Eq/kg) IV over 1-2 hours; max 100 m L/dose. Correction rate max 0.5 m Eq/L/h.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Initiate at lower end of adult dose; monitor volume status and serum sodium closely due to reduced renal function and higher risk of fluid overload.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Rapid correction of chronic hyponatremia (>0.5 m Eq/L/h) may cause osmotic demyelination syndrome (central pontine myelinolysis). Infusion rate must be carefully monitored.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of fluid overload, especially in patients with heart failure, renal impairment, or cirrhosis,Risk of hypernatremia and hyperchloremic metabolic acidosis with excessive administration,Extravasation may cause tissue necrosis,Use with caution in patients with impaired renal function, electrolyte abnormalities, or conditions predisposing to fluid overload
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypernatremia,Hypersensitivity to sodium chloride,Fluid retention states such as congestive heart failure, pulmonary edema, or peripheral edema,Severe renal impairment with oliguria or anuria
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. Maintain a consistent dietary sodium intake as advised by your healthcare provider; avoid excessive water intake during treatment.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
SODIUM CHLORIDE 23.4% is a hypertonic saline solution used for correction of severe hyponatremia or as an osmotic agent. Teratogenicity is not expected from sodium chloride itself; however, rapid correction of hyponatremia may cause maternal osmotic demyelination, which could secondarily affect fetal well-being. No direct fetal risks are documented in the first trimester. In second and third trimesters, excessive sodium administration may cause maternal hypernatremia and volume expansion, potentially leading to placental edema or fetal hypernatremia. Use cautiously and avoid extreme electrolyte shifts.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Sodium chloride is a normal constituent of breast milk. Hypertonic saline administration may transiently increase milk sodium content. The milk-to-plasma (M/P) ratio for sodium is approximately 1.0 due to passive diffusion. Clinically significant effects on the breastfed infant are unlikely with appropriate dosing. However, high maternal doses causing hypernatremia could theoretically lead to hypernatremia in the infant. Monitor infant for signs of salt overload.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy does not require dose adjustments for sodium chloride per se. However, physiologic plasma volume expansion in pregnancy may dilute serum sodium, potentially increasing the risk of overcorrection of hyponatremia. Use lower infusion rates and more frequent monitoring of serum sodium. Maximum rate of correction should not exceed 10-12 m Eq/L in 24 hours to avoid osmotic demyelination. No pharmacokinetic changes specific to pregnancy necessitate dose changes.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
23.4% sodium chloride is a hypertonic solution used primarily for severe hyponatremia (serum Na+ <120 m Eq/L with neurological symptoms). Administer via central line only due to high osmolarity (8000 m Osm/L). Infuse at 1-2 m L/min with frequent serum Na+ monitoring; target correction rate ≤8 m Eq/L in 24 hours to prevent osmotic demyelination syndrome. Do not use in patients with heart failure, renal impairment, or hypervolemia.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is used to correct severely low sodium levels in the blood.,It must be given through a large vein (central line) to prevent damage to small veins.,Your sodium levels and neurological status will be monitored closely during infusion.,Report any symptoms like headache, nausea, confusion, or muscle twitching immediately.,Do not adjust the infusion rate yourself; it is controlled by medical staff.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 23.4% is a hypertonic saline solution that increases serum osmolality, drawing water from intracellular space into extracellular space, thereby expanding intravascular volume and reducing cerebral edema. It also acts as an electrolyte replenisher.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is: IV: 50-100 m L of 23.4% sodium chloride (11.7-23.4 g Na Cl) infused over 1-2 hours for hyponatremia; rate not to exceed 0.5 m Eq/L/h correction.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is classified as Category A/B. SODIUM CHLORIDE 23.4% is a hypertonic saline solution used for correction of severe hyponatremia or as an osmotic agent. Teratogenicity is not expected from sodium chloride itself;. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.